Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug. | ...

Cytokinetics (CYTK) shares have moved in line with broader biotech trends, as investors pay close attention to recent performance data. Over the past month, the stock has climbed 15%, reflecting ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Preview this article 1 min AI companies need more than office space, the CEO of this real estate developer says. Genentech's ...

ACB says the acquisition of immovable properties and other assets, in India and abroad, may be examined in detail during the ...

Alexandria Real Estate Equities, Inc. faces ongoing headwinds, with soft biotech demand, and declining occupancy. Learn more ...

The pharmaceutical giant has avoided a board spill, but 42 per cent of shareholders voted against executive remuneration in a ...

Australian biotech giant CSL has delayed its vaccine division spin-off due to a drastic decline in US flu immunization rates, leading to a 16.6% drop in share price. The company's revenue and profit ...

The head of an Australian biotech business has blamed lower vaccination rates in the US as a key factor behind the company's ...

Novartis will pay $72 a share in cash for the biotechnology company, representing a premium of 46% to Avidity’s closing price ...

(Oct 27): Novartis AG agreed to buy biotechnology company Avidity Biosciences Inc in a deal valued at US$12 billion, making ...